QUANTUM BIOPHARMA-B SUB VOT (QNTM) Fundamental Analysis & Valuation

NASDAQ:QNTM • CA74764Y2050

Current stock price

5.55 USD
-0.18 (-3.14%)
At close:
5.5534 USD
+0 (+0.06%)
After Hours:

This QNTM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. QNTM Profitability Analysis

1.1 Basic Checks

  • QNTM had negative earnings in the past year.
  • QNTM had a negative operating cash flow in the past year.
  • QNTM had negative earnings in each of the past 5 years.
  • In the past 5 years QNTM always reported negative operating cash flow.
QNTM Yearly Net Income VS EBIT VS OCF VS FCFQNTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • QNTM's Return On Assets of -234.53% is on the low side compared to the rest of the industry. QNTM is outperformed by 93.19% of its industry peers.
  • QNTM's Return On Equity of -378.01% is on the low side compared to the rest of the industry. QNTM is outperformed by 82.72% of its industry peers.
Industry RankSector Rank
ROA -234.53%
ROE -378.01%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QNTM Yearly ROA, ROE, ROICQNTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for QNTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNTM Yearly Profit, Operating, Gross MarginsQNTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. QNTM Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for QNTM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
QNTM Yearly Shares OutstandingQNTM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M
QNTM Yearly Total Debt VS Total AssetsQNTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -26.29, we must say that QNTM is in the distress zone and has some risk of bankruptcy.
  • QNTM's Altman-Z score of -26.29 is on the low side compared to the rest of the industry. QNTM is outperformed by 89.53% of its industry peers.
  • QNTM has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
  • QNTM has a worse Debt to Equity ratio (0.26) than 62.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z -26.29
ROIC/WACCN/A
WACCN/A
QNTM Yearly LT Debt VS Equity VS FCFQNTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 1.07 indicates that QNTM should not have too much problems paying its short term obligations.
  • QNTM's Current ratio of 1.07 is on the low side compared to the rest of the industry. QNTM is outperformed by 84.29% of its industry peers.
  • A Quick Ratio of 1.06 indicates that QNTM should not have too much problems paying its short term obligations.
  • QNTM's Quick ratio of 1.06 is on the low side compared to the rest of the industry. QNTM is outperformed by 80.10% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 1.06
QNTM Yearly Current Assets VS Current LiabilitesQNTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. QNTM Growth Analysis

3.1 Past

  • QNTM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.49%, which is quite impressive.
EPS 1Y (TTM)43.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNTM Yearly Revenue VS EstimatesQNTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 100K 200K 300K
QNTM Yearly EPS VS EstimatesQNTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 -100 -200 -300 -400

More info and screens

Find the best growth stocksShow best growing peers

0

4. QNTM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for QNTM. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNTM Price Earnings VS Forward Price EarningsQNTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNTM Per share dataQNTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. QNTM Dividend Analysis

5.1 Amount

  • QNTM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

QNTM Fundamentals: All Metrics, Ratios and Statistics

QUANTUM BIOPHARMA-B SUB VOT

NASDAQ:QNTM (5/1/2026, 8:00:01 PM)

After market: 5.5534 +0 (+0.06%)

5.55

-0.18 (-3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength33.59
Industry Growth45.52
Earnings (Last)03-26
Earnings (Next)05-12
Inst Owners14.17%
Inst Owner Change77.91%
Ins Owners11.96%
Ins Owner ChangeN/A
Market Cap21.59M
Revenue(TTM)N/A
Net Income(TTM)-26.18M
Analysts82.86
Price Target36.72 (561.62%)
Short Float %5.5%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.42%
PT rev (3m)10.32%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.12
P/tB 8.95
EV/EBITDA N/A
EPS(TTM)-8.72
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS0
BVpS1.78
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -234.53%
ROE -378.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 1.06
Altman-Z -26.29
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.78%
OCF growth 3YN/A
OCF growth 5YN/A

QUANTUM BIOPHARMA-B SUB VOT / QNTM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for QUANTUM BIOPHARMA-B SUB VOT?

ChartMill assigns a fundamental rating of 1 / 10 to QNTM.


Can you provide the valuation status for QUANTUM BIOPHARMA-B SUB VOT?

ChartMill assigns a valuation rating of 0 / 10 to QUANTUM BIOPHARMA-B SUB VOT (QNTM). This can be considered as Overvalued.


How profitable is QUANTUM BIOPHARMA-B SUB VOT (QNTM) stock?

QUANTUM BIOPHARMA-B SUB VOT (QNTM) has a profitability rating of 0 / 10.


Can you provide the financial health for QNTM stock?

The financial health rating of QUANTUM BIOPHARMA-B SUB VOT (QNTM) is 2 / 10.